Views & Analysis Addressing MS’ two-tier healthcare system is about ‘social j... NICE has reversed its decision not to approve a new drug that offers hope to thousands o
Views & Analysis Listening to the Patient Voice: seek out the quietest voice ... The success or failure of patient centricity rests on getting the patient voice in the mix – not just listening to those who shout the loudest.
Views & Analysis Case study: Ensuring safety by digitally linking prescriptio... Monitoring people who are on disease modifying drugs (DMDs) is paramount to providing safe, high-quality MS care.
Views & Analysis Addressing the growing need for better Multiple Sclerosis ca... Jo Sopala of the MS Trust describes the organisation's work in creating better multiple sclerosis care.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
